Prophylactic Vitamin K Dosing for Bleeding Prevention in PSC
For patients with PSC requiring bleeding prophylaxis, administer 10 mg of vitamin K (phytomenadione) subcutaneously as the standard dose, with oral administration of 10-20 mg as an alternative route when parenteral administration is not feasible.
Evidence-Based Dosing Recommendations
The most recent PSC guidelines 1 from the British Society of Gastroenterology (2019) and EASL guidelines 2 (2022) emphasize that fat-soluble vitamin deficiency is relatively common in advanced PSC and clinicians should have a low threshold for empirical replacement 1. However, these guidelines do not specify exact prophylactic vitamin K doses.
Standard Dosing Protocol
Based on FDA labeling 3 and clinical evidence:
- Subcutaneous route (preferred): 10 mg vitamin K1 is the standard dose for correcting hypoprothrombinemia in adults
- Oral route (alternative): 10-20 mg has been studied effectively 4
- Frequency: Determined by INR monitoring and clinical response
- Timing: Response typically occurs within 24-48 hours, with measurable PT improvement in 2-4 hours minimum 3
Route Selection
Subcutaneous administration is strongly preferred over intravenous 3. The FDA label explicitly warns that IV administration should only be used "when considered unavoidable" and must be given slowly (not exceeding 1 mg/minute) due to risk of anaphylactoid reactions 3.
Oral administration (10-20 mg) has been shown equally effective as IV phytomenadione (10 mg) in correcting coagulopathies associated with cholestasis, with no adverse reactions 4. This simplifies outpatient management.
Critical Caveats and Monitoring
When Vitamin K May NOT Work
Vitamin K is ineffective in severe hepatic synthetic dysfunction 5. A 2013 study demonstrated that vitamin K administration in cirrhotic patients did not significantly improve Factor VII, protein C, or protein S levels across different stages of liver disease 5. This suggests that vitamin K deficiency in PSC is primarily due to cholestasis-related malabsorption, not hepatic synthetic failure.
Key Monitoring Points
- Check baseline INR/PT before administration
- Reassess at 72 hours: If no improvement, vitamin K deficiency is unlikely the cause 5
- Do not expect immediate effect: Minimum 1-2 hours for measurable improvement 3
- Consider fresh frozen plasma if active bleeding with severe coagulopathy 3
Clinical Context in PSC
Recent data 6 (2025) shows that more than half of PSC patients have suboptimal vitamin K intake, with 40% having poor overall dietary quality. This supports the guideline recommendation 1 for low threshold empirical replacement in advanced disease.
Risk Stratification for Prophylaxis
Consider prophylactic vitamin K in PSC patients with:
- Advanced disease (cirrhosis, portal hypertension)
- Prolonged cholestasis (elevated bilirubin, alkaline phosphatase)
- Prior to invasive procedures (ERCP, liver biopsy)
- Documented fat-soluble vitamin deficiencies
- Poor nutritional status
Procedure-Specific Dosing
For patients undergoing ERCP with elevated INR, the evidence 4 supports 10-20 mg oral vitamin K given 3 days prior to procedure (20 mg daily × 3 days was effective in one study). However, if INR >1.5 and procedure is urgent, use 10 mg subcutaneous with reassessment in 24 hours.
Important Warnings
- Vitamin K does NOT counteract heparin 3
- Avoid IV route due to anaphylactoid risk 3
- Benzyl alcohol preservatives are toxic in neonates but safe in recommended adult doses 3
- Aluminum content may accumulate with prolonged use in renal impairment 3
- Failure to respond indicates either severe hepatic dysfunction or non-vitamin K-related coagulopathy 3, 5